Articles tagged "HLA antibodies"

2019 American Transplant Congress
Outcomes of Induction Therapy with Bortezomib and High-Dose Intravenous Immunoglobulin for Kidney Transplantation with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies
Y. Miyauchi, T. Noda, N. Miura, T. Kikugawa, T. Saika
Department of Urology, Ehime University, Toon, Japan
*Purpose: Preformed donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) are known to increase the risk of antibody-mediated rejection (ABMR) and graft failure. However, effective methods…
2019 American Transplant Congress
Computational Assessment of T-cell and B-cell Allorecognition to Predict Donor HLA Immunogenicity
H. C. Copley¹, M. Elango¹, V. Kosmoliaptsis²
¹Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospital, Cambridge, United Kingdom, ²University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospital & NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation at the University of Cambridge, Cambridge, UK., Cambridge, United Kingdom
*Purpose: Donor-specific alloantibody (DSA) development after solid-organ transplantation is a major cause of graft loss, and limits future transplant options. We have previously shown that…
2019 American Transplant Congress
Back Signaling of HLA Class I Molecules and NK Cell Receptor Ligands in Renal Epithelial Cells Contributes to the Rejection-Specific Microenvironment
E. Chichelnitskiy¹, J. Egelkamp¹, K. Daemen¹, J. Keil¹, C. Neudörfl¹, J. Bräsen², J. Schmitz², H. Haller³, C. Blume⁴, C. Falk⁵
¹Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany, ²Nephropathology Unit, Institute of Pathology, Hannover Medical School, Hannover, Germany, ³Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany, ⁴Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany; Institute of Technical Chemistry, Leibniz University, Hannover, Germany, ⁵Institute of Transplant Immunology, Hannover Medical School; DZIF, German Center for Infection Research, TTU-IICH, Hannover/Braunschweig, Germany
*Purpose: During the last years, diverse harming mechanisms of donor-specific antibodies (DSA) to endothelial cells have been studied accompanied by an emerging evidence of NK…
2019 American Transplant Congress
Patients with Immunological Diseases or on Peritoneal Dialysis Are Prone to False Positive Flow Cytometry Cross Match
Q. Xu¹, A. House², S. Leckie¹, L. Gunaratnam², P. Luke³, A. Jevnikar²
¹Pathology and Lab Medicine, London Health Science Center, London, ON, Canada, ²Medicine, Western University, London, ON, Canada, ³Surgery, Western University, London, ON, Canada
*Purpose: Despite implementation of virtual cross matches, flow cytometry cross matches (FCXM) are still used by many transplant centers to determine immunological risk prior to…
2019 American Transplant Congress
Conversion from Calcineurin Inhibitors to Belatacept in Kidney Recipients with Donor-Specific Anti-HLA Antibodies and Calcineurin Inhibitor Nephrotoxicity Decreases the Pathogenicity of Donor-Specific Anti-HLA Antibodies
K. Louis¹, D. Viglietti¹, D. Pievani¹, O. Aubert¹, D. Glotz¹, C. Legendre¹, A. Zeevi², A. Loupy¹, C. Lefaucheur¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France, ²University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Switching from CNI- to Belatacept-based regimen has been associated with improved graft function in low-immunologic risk kidney recipients. We investigated the efficacy and safety…
2019 American Transplant Congress
Single Center Deceased Donor Renal Transplant (DDRTx) Outcomes in Sensitized Patients after Implementation of the Kidney Allocation System (KAS)
S. S. Patel, K. L. King, J. Kamal, E. Vasilescu, A. Husain, S. Mohan, L. E. Ratner, R. Crew
Columbia University Irving Medical Center, New York, NY
*Purpose: Introduction of KAS in 2014 prioritized access to DDRTx for highly-sensitized candidates although it was unclear whether the outcomes would be acceptable in this…
2019 American Transplant Congress
Report of 20 HLAMatchmaker Eplets Present on Denatured Class I HLA Molecules
R. de Marco¹, A. C. Lima², N. F. Pereira², M. Gerbase-DeLima¹
¹Immunogenetics Institute, AFIP, Sao Paulo, SP, Brazil, ²Immunogenetics Laboratory, Universidade Federal do Paraná, Curitiba, PR, Brazil
*Purpose: The purpose of this report is to describe 20 class I HLA eplets, herein called FakEplets, present on denatured HLA molecules.*Methods: The study included…
2019 American Transplant Congress
Clazakizumab as an Agent to Reduce Donor Specific HLA Antibodies and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation
S. C. Jordan¹, N. Ammerman¹, M. Toyoda², E. Huang¹, C. C. Nast³, A. Peng¹, S. Sethi¹, R. Najjar¹, I. Kim¹, K. Lim¹, J. Choi¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA, ³Department of Pathology, Cedars-Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production.…
2019 American Transplant Congress
Long Term Outcomes in Kidney Transplant Recipients Receiving Everolimus (EVR) or Mycophenolate (MPS) in Combination with Tacrolimus (TAC)
K. Ficher, C. Rosso Felipe, Y. Cardoso Dreige, K. Linhares, A. Ferreira Brígido, S. Stopa, L. Viana, M. Cristelli, P. Gessolo Lins, W. Aguiar, H. Proença, R. Marco, M. Gerbase de Lima, H. Tedesco Silva Junior, J. Medina Pestana
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Detailed long-term data comparing the use of EVR or MPS in kidney transplant recipients receiving TAC is lacking.*Methods: This is a 5-years extension analysis…
2019 American Transplant Congress
Improving Pre-Kidney Transplantion Laboratory Utilization in an Era of Increasing Waitlist Size
G. K. Mahowald¹, B. Kimball², N. Elias², E. Heher³, T. Girouard¹, S. L. Saidman¹, V. Pattanayak¹
¹Pathology, Massachusetts General Hospital, Boston, MA, ²Transplant Surgery, Massachusetts General Hospital, Boston, MA, ³Nephrology, Massachusetts General Hospital, Boston, MA
*Purpose: Beginning on March 25, 2015, our institution’s kidney transplant program has implemented a “readiness” protocol, whereby patients are listed after limited workup and comprehensive…